The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-06-30

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine genetic factors that affect responses to niacin therapy and endotoxemia in healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

NCT01969370

Cancer Cardiovascular Disease Neurologic Dysfunction +2 more

COMPLETED NA

The Role of Genetic Polymorphisms in Innate Immune Response Genes in Susceptibility to Infections

NCT00597090

Infections

COMPLETED

Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19

NCT04426253

COVID-19 Sars-CoV2

UNKNOWN

Human Genomic Population Structure and Phenotype-genotype Variation in ADME Genes in Four Populations

NCT02789527

Healthy

COMPLETED NA

Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana

NCT04083261

New York Medical Marijuana Program Qualifying Conditions

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Niacin is a vitamin that has beneficial effects on cholesterol (a type of fat in the blood) when used in high doses. Different people respond differently to cholesterol lowering doses of niacin, some people have a side effect termed flushing (similar to a hot flash) while others do not and some people have more pronounced effects on cholesterol. Endotoxin or lipopolysaccharide (LPS) is a small part of bacteria (that is no longer living) that can cause many of the effects similar to bacterial infections in humans. However, it can be administered in very small amounts to produce a mild inflammatory response much the same as a 'flu-like" illness. Within 1 ½ -3 hours after giving LPS by vein, a response consisting of fever, chills, headache, nausea and vomiting and generalized aches and pains will occur which lasts up to 6-8 hours. In addition to the flu like symptoms, the inflammation causes changes in cholesterol, triglycerides and glucose clearance. Different people respond differently to endotoxin and inflammation. We are performing this study to see if there are genetic factors that predict how people will respond to niacin and to endotoxin and its inflammatory response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Niacin and Endotoxin

All subjects are expected to have the same interventions- Niacin and Endotoxin.

Group Type EXPERIMENTAL

Immediate Release Niacin, Extended Release Niacin, Endotoxin

Intervention Type DRUG

Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immediate Release Niacin, Extended Release Niacin, Endotoxin

Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Niacor Niaspan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and non-pregnant/lactating women between the ages of 18 and 45.
2. Self reported African American or Caucasian racial-ethnic background.
3. Body Mass Index (BMI) of ≥ 18 and ≤ 30.
4. Participants who are able to give written informed consent and willing to comply with all study-related procedures.

Exclusion Criteria

1. Known clinically manifest atherosclerotic cardiovascular disease, including coronary disease, cerebrovascular disease, or peripheral vascular disease.
2. History of diabetes mellitus.
3. Fasting glucose \> 126 mg/dL.
4. History of a non-skin malignancy within the previous 5 years.
5. Renal insufficiency as defined by creatinine \> 1.5 mg/dl at Screening Visit.
6. History of liver disease or abnormal liver function tests (LFTs) (AST, ALT, Alk. Phos., GGT \> 1.5x upper limit of normal (ULN); bilirubin \> 2x ULN) at Screening Visit.
7. Men who are unwilling to limit alcohol consumption to \<14 alcoholic drinks per week or \< 4 alcoholic drinks per occasion (AMA / NIAAA criteria for "at risk" usage levels) while participating in the study.
8. Women who are unwilling to limit alcohol consumption to \< 7 alcoholic drinks per week or \< 3 alcoholic drinks per occasion (AMA / NIAAA criteria for "at risk" usage levels) while participating in the study.
9. Total white blood cell count less than or equal to 3.0 THO/uL.
10. Hemoglobin below 11.0 g/dL.
11. Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory condition or minor active infection.
12. History of HIV positive.
13. First degree family history of premature cardiovascular disease event (father or brother if diagnosed at before 55 years of age; mother or sister if diagnosed before 65 years of age).
14. Patients who have undergone any organ transplant.
15. Individuals who currently use tobacco products or have done so in the previous 30 days.
16. Treatment with aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, steroids or any immunomodulatory therapy 2 weeks prior to the Screening Visit.
17. Treatment with statins, fibrates or niacin 4 weeks prior to the Screening Visit.
18. Current daily use of Vitamin C \> 1000 mg, Beta carotene \> 1000 IU, vitamin A \> 5000 IU, vitamin E \> 400 IU, and selenium \> 200 mcg.
19. Positive urine pregnancy at the Screening Visit.
20. Participation in another clinical trial within the previous 6 weeks prior to the Screening Visit.
21. Poorly controlled blood pressure (BP \> 160/110) or on any anti-hypertensive medications.
22. A diagnosis of metabolic syndrome using updated 2004 NCEP ATPIII criteria.
23. A history of severe lactose intolerance (e.g., intolerance of any milk intake).
24. Any medical condition or abnormal laboratory value that is judged clinically significant by an investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes